8-K: Akebia Reports Q2 2025 Profit, Strong Vafseo Growth

Akebia Therapeutics announced a return to net income in Q2 2025, driven by significant growth in Vafseo sales and strategic partnerships.

Summary

• Akebia Therapeutics reported total revenues of $62.5 million for the second quarter ended June 30, 2025, an increase from $43.6 million in Q2 2024.
• The company achieved a net income of $0.2 million in Q2 2025, a significant improvement from a net loss of $8.6 million in Q2 2024.
• Vafseo net product revenue reached $13.3 million in Q2 2025, with prescription demand growing approximately 55% over Q1 2025.
• More than 725 prescribers wrote a prescription for Vafseo in Q2 2025, with over 80% being refill prescriptions.
• Auryxia net product revenue was $47.2 million in Q2 2025, up from $41.2 million in Q2 2024, despite loss of exclusivity on March 20, 2025.
• Cash and cash equivalents stood at approximately $137.3 million as of June 30, 2025, compared to $51.9 million at December 31, 2024.
• DaVita is expected to begin treating patients with Vafseo in an operational pilot across more than 100 clinics in August 2025.
• Dialysis Clinics, Inc. (DCI) and Innovative Renal Care (IRC) are expected to operationalize protocols for Vafseo prescribing by September 2025, expanding access to over 75,000 patients.
• Patient enrollment was completed in the VOICE clinical trial of Vafseo, with top-line data expected in early 2027.
• Akebia initiated the VOCAL trial to evaluate three times per week dosing of vadadustat in approximately 350 hemodialysis patients.
• The company is working towards initiating the VALOR Phase 3 clinical trial for vadadustat in late-stage CKD patients not on dialysis by the end of 2025.

Sentiment

Score: 8

Explanation: The filing indicates strong positive momentum with a return to profitability, significant revenue growth driven by Vafseo's successful launch and expanding market access through key partnerships (DaVita, DCI, IRC). The robust cash position and ongoing clinical development for label expansion further support a very positive outlook, despite inherent biopharma risks and non-cash expenses.

Positives

• Achieved net income of $0.2 million in Q2 2025, a substantial improvement from a net loss of $8.6 million in Q2 2024.
• Total revenues increased significantly to $62.5 million in Q2 2025 from $43.6 million in Q2 2024.
• Vafseo net product revenue grew to $13.3 million in Q2 2025, with prescription demand increasing by approximately 55% over Q1 2025.
• Successful expansion of Vafseo prescriber base, with over 725 prescribers in Q2 2025 and over 80% refill prescriptions.
• DaVita, a leading dialysis organization, began ordering Vafseo for an operational pilot in Q3 2025, expected to lead to broad prescribing.
• DCI and IRC, the fourth and fifth largest dialysis organizations, are expected to operationalize Vafseo prescribing protocols by September 2025, expanding patient access to over 75,000.
• Auryxia net product revenues increased to $47.2 million in Q2 2025 despite loss of exclusivity, with only one authorized generic on the market.
• Completed patient enrollment in the VOICE clinical trial (2,116 patients), with top-line data anticipated in early 2027.
• Initiated the VOCAL trial to evaluate three times per week dosing of Vafseo, demonstrating continued clinical development.
• Progressing towards initiating the VALOR Phase 3 clinical trial for non-dialysis CKD patients by the end of 2025.
• Cash and cash equivalents increased to $137.3 million as of June 30, 2025, from $51.9 million at year-end 2024.
• Management believes the company is financed to achieve profitability based on its current operating plan.

Negatives

• Incurred $7.0 million in non-cash expense related to the change in fair value of warrant liability in Q2 2025.
• Recorded $5.4 million in non-cash interest expense related to the settlement royalty liability from the Vifor Termination and Settlement Agreement.
• Vafseo-related cost of goods sold in Q2 2025 was derived from pre-launch inventory, meaning a portion of manufacturing costs were previously expensed as R&D, which may not reflect full future manufacturing costs.
• License, collaboration and other revenues decreased to $2.0 million in Q2 2025 from $2.4 million in Q2 2024.

Risks

• VAFSEO carries a Boxed Warning for increased risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access, especially with hemoglobin levels greater than 11 g/dL.
• Potential for hepatotoxicity, requiring monitoring of ALT, AST, and bilirubin levels; not recommended in patients with cirrhosis or active, acute liver disease.
• Risk of worsening hypertension, including hypertensive crisis, requiring blood pressure monitoring and adjustment of anti-hypertensive therapy.
• Risk of seizures, necessitating monitoring for new-onset seizures or changes in frequency.
• Increased risk of gastrointestinal (GI) erosion, including GI bleeding, requiring patient advisement and prompt medical care if symptoms occur.
• Safety of VAFSEO has not been established for anemia due to CKD in adults not on dialysis, with observed increased risks of mortality, stroke, MI, acute kidney injury, hepatic injury, and GI erosions in this population.
• VAFSEO is not recommended in patients with active malignancies.
• Drug interactions with iron supplements, iron-containing phosphate binders, non-iron-containing phosphate binders, BCRP substrates, and statins (e.g., simvastatin and rosuvastatin dose limits).
• Potential for fetal harm if used during pregnancy and not recommended for breastfeeding until two days after the final dose.
• Uncertainty regarding the potential therapeutic benefits, safety profile, and effectiveness of Vafseo in broader patient populations or long-term use.
• Regulatory risks, including decisions by health authorities like the FDA, which could impact approvals or label expansions.
• Market acceptance, coverage, and reimbursement for Vafseo may not meet expectations, affecting demand and revenue.
• Competitive landscape for Auryxia and Vafseo, including the timing and impact of generic entrants.
• Ability to attract and retain qualified personnel crucial for continued operations and growth.
• Ability to achieve and maintain profitability and manage operating expenses effectively.
• Manufacturing, supply chain, and quality control issues, including potential recalls or write-downs.
• Risk of early termination of collaboration agreements.
• Impact of changes in the geopolitical environment and U.S. trade policy on tariffs.

Future Outlook

Akebia expects continued Vafseo growth, with DaVita's operational pilot leading to broad prescribing before year-end. Dialysis Clinics, Inc. (DCI) and Innovative Renal Care (IRC) are anticipated to operationalize Vafseo protocols by September, expanding patient access to over 75,000. The company aims to make Vafseo the standard of care for anemia in CKD patients and plans to initiate the VALOR Phase 3 clinical trial for non-dialysis CKD patients by the end of 2025. Top-line data from the VOICE trial is expected in early 2027. Akebia believes it is financed to achieve profitability based on its current operating plan, which includes pursuing label expansion for Vafseo and advancing other existing programs.

Management Comments

• "Vafseo (vadadustat) U.S. product launch momentum builds as we continued to add new prescribers, increase volume with existing writers, and importantly, progress efforts to further expand patient access to the therapy."
• "We are working to increase utilization at mid-sized dialysis organizations, and we expect by September, both Dialysis Clinics, Inc. (DCI) and Innovative Renal Care (IRC), the fourth and fifth largest dialysis organizations, will have operationalized protocols to simplify and expand Vafseo prescribing."
• "Additionally, we are pleased that DaVita has begun ordering Vafseo to support an operational pilot in Q3, which we expect to lead to the opportunity for broad prescribing before year end."
• "I am also excited about the progress we have made executing on our post-marketing development strategy, which is critical to our ultimate goal of making Vafseo the standard of care for the treatment of anemia in patients with chronic kidney disease (CKD)."

Industry Context

The announcement highlights Akebia's focus on the chronic kidney disease (CKD) market, particularly anemia management in dialysis patients, a significant and underserved area. The partnerships with major dialysis organizations like DaVita, DCI, and IRC are crucial for market penetration and adoption of Vafseo, positioning it against existing erythropoietin stimulating agents (ESAs). The ongoing clinical trials (VOICE, VOCAL, VALOR) demonstrate a commitment to expanding Vafseo's utility and potentially challenging the current standard of care, reflecting a broader industry trend towards novel oral therapies for chronic conditions.

Comparison to Industry Standards

• The VOICE trial is designed to measure non-inferiority of Vafseo versus standard-of-care erythropoietin stimulating agents (ESAs) using hierarchical endpoints of all-cause mortality and all-cause hospitalization, directly comparing Vafseo's efficacy and safety profile to established treatments in the market.
• The VOCAL trial will evaluate three times per week (TIW) dosing of vadadustat compared to standard of care ESAs, aiming to demonstrate potential advantages in dosing frequency and patient convenience over existing injectable ESA therapies.
• The VALOR Phase 3 trial aims to study vadadustat for treating anemia in late-stage CKD patients who are not on dialysis, a patient population where Vafseo's safety has not been established and where current ESA use is prevalent, indicating an attempt to expand market reach beyond the current dialysis-dependent indication.

Stakeholder Impact

• **Shareholders:** Positive financial results, including a return to net income and strong revenue growth, coupled with expanding market access for Vafseo, could lead to increased shareholder value and confidence.
• **Patients:** Expanded access to Vafseo through partnerships with major dialysis organizations like DaVita, DCI, and IRC could improve treatment options for patients with anemia due to CKD on dialysis. Ongoing clinical trials aim to further expand treatment options and potentially improve outcomes.
• **Prescribers/Healthcare Providers:** Operationalized protocols from major dialysis organizations are expected to simplify and expand Vafseo prescribing, making it easier for physicians to integrate the therapy into patient care.
• **Employees:** The company's improved financial health and strategic growth initiatives suggest stability and potential for continued employment and growth opportunities.
• **Competitors:** The successful launch and market penetration of Vafseo, along with ongoing clinical trials, could intensify competition in the anemia of CKD treatment market, particularly for existing ESA manufacturers.

Next Steps

• Akebia will host a conference call on August 7, 2025, to discuss Q2 2025 earnings.
• DaVita physicians are expected to begin treating patients with Vafseo in an operational pilot in August 2025, with expectations for broad prescribing before year-end.
• Dialysis Clinics, Inc. (DCI) and Innovative Renal Care (IRC) are expected to operationalize Vafseo prescribing protocols by September 2025.
• Akebia plans to initiate the VALOR Phase 3 clinical trial for vadadustat in late-stage CKD patients not on dialysis by the end of 2025.
• Top-line data from the VOICE clinical trial is expected in early 2027.

Key Dates

Recommendation

The company has demonstrated a significant financial turnaround, moving from a net loss to net income in Q2 2025, driven by robust revenue growth. The commercial launch of Vafseo is gaining strong momentum, evidenced by a 55% increase in prescription demand and successful partnerships with major dialysis organizations like DaVita, DCI, and IRC, which are expected to significantly expand patient access. The strong cash position and ongoing clinical development programs for label expansion indicate a clear strategic path for future growth and profitability. While biopharma investments carry inherent risks, the current trajectory and strategic execution suggest a compelling investment opportunity.

Keywords

Biopharmaceutical, Kidney disease, Anemia, Vafseo, Vadadustat, Auryxia, Ferric citrate, Dialysis, CKD, Clinical trial, Financial results, Q2 2025, Akebia Therapeutics, DaVita, DCI, IRC